New cancer drug DXC014 enters first human tests

NCT ID NCT07177937

Recruiting now Disease control Sponsor: Hangzhou DAC Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. Participants must have a life expectancy of at least 3 months and be in fairly good health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma neoplasm prostate cancer small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA OTHER ADVANCED SOLID TUMORS PROSTATE CANCER SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, Hunan, 410000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Peking University First Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100034, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

Contact Phone: •••-•••-•••• Email: •••••@•••••